Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
Her2-positive Lung Cancer Treated With Dedicated Drug
- Conditions
- Non Small Cell Lung Cancer MetastaticHER2 Gene MutationNon Small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Target Recruit Count
- 46
- Registration Number
- NCT03845270
- Locations
- 🇫🇷
Montpellier - CHRU, Montpellier, France
🇫🇷Centre Hospitalier - Pneumologie, Le Mans, France
🇫🇷Hôpital Nord APHM, Marseille, France
Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 39
- Registration Number
- NCT03820141
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
- Conditions
- Advanced Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- iOMEDICO AG
- Registration Number
- NCT03811418
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Conditions
- Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 138
- Registration Number
- NCT03747120
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸New Mexico Cancer Center, Albuquerque, New Mexico, United States
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 8
- Registration Number
- NCT03742986
- Locations
- 🇺🇸
Indiana University, Bloomington, Indiana, United States
🇺🇸NYU Langone Health, New York, New York, United States
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 454
- Registration Number
- NCT03726879
- Locations
- 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03716180
- Locations
- 🇺🇸
DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
- Conditions
- HER2-Positive Early Breast Cancer
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT03674112
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Texas Oncology - Memorial City, Houston, Texas, United States
🇨🇺Hospital Hermanos Ameijeiras, La Habana, Cuba
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Conditions
- Estrogen Receptor Positive TumorBreast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 147
- Registration Number
- NCT03644186
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Berard, Lyon, France
🇮🇹Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Conditions
- Invasive Breast Cancer
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 650
- Registration Number
- NCT03595592
- Locations
- 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸Hospital Virgen de la Nieves, Granada, Spain
🇮🇹Ospedale Santa Maria della Misericordia, Udine, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.